05.30.06
Rentschler Biotechnologie GmbH has signed a contract with Maxygen Holdings Ltd., a wholly owned subsidiary of Maxygen, Inc., for the manufacture of a novel factor VIIa protein therapeutic. This follows a recent agreement between Maxygen and Roche to co-develop and commercialize the protein for multiple clinical indications.
Rentschler will set up the GMP-process and manufacture the drug to supply the clinical studies. Additionally, Maxygen and Roche have an option to retain Rentschler as contract manufacturer for late stage clinical and commercial supplies.
Dr. Nikolaus F. Rentschler, chief executive officer of Rentschler said, “We are very pleased about Maxygen’s decision to expand the cooperation of our companies. In the light of the successful ongoing collaboration on Maxygen’s next-generation G-CSF project we take this as a sign of confidence in our professional skills. We will be fully committed to contributing to the success of this novel drug project.”
Factor VIIa is a natural protein with a pivotal role in blood coagulation and clotting. Maxygen’s novel protein will be evaluated for its therapeutic potential in new indications such as severe bleeding in trauma and intracerebral haemorrhage (ICH).
Rentschler will set up the GMP-process and manufacture the drug to supply the clinical studies. Additionally, Maxygen and Roche have an option to retain Rentschler as contract manufacturer for late stage clinical and commercial supplies.
Dr. Nikolaus F. Rentschler, chief executive officer of Rentschler said, “We are very pleased about Maxygen’s decision to expand the cooperation of our companies. In the light of the successful ongoing collaboration on Maxygen’s next-generation G-CSF project we take this as a sign of confidence in our professional skills. We will be fully committed to contributing to the success of this novel drug project.”
Factor VIIa is a natural protein with a pivotal role in blood coagulation and clotting. Maxygen’s novel protein will be evaluated for its therapeutic potential in new indications such as severe bleeding in trauma and intracerebral haemorrhage (ICH).